Oric Pharmaceuticals Inc (ORIC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $814.71M
Last updated: Nov 17, 2026 at 11:06 AM ET
Oric Pharmaceuticals Inc (ORIC) Stock Forecast
Analysts expect Oric Pharmaceuticals (ORIC) to earn -$1.49 per share in the fiscal year ending Dec 31, 2026. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.93, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 12 | 80.0% |
| Hold | 1 | 6.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.49
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.69
- EPS consensus
- Next report
- Feb 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.49 | -$1.64 to -$1.25 | 13 |
| Dec 31, 2027 | -$1.69 | -$1.98 to -$1.37 | 13 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.46 to -$0.35 | 16 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.47.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.49 | -$1.49 | -$1.48 | -$1.48 | -$1.47 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.69 | -$1.67 | -$1.65 | -$1.61 | -$1.61 | N/A |
Frequently Asked Questions About ORIC
What is the ORIC stock forecast?
Consensus analyst estimates put Oric Pharmaceuticals's EPS at -$1.49 for the fiscal year ending Dec 31, 2026. The consensus rating from 15 analysts is Buy.
How do analysts rate ORIC stock?
Of 15 analysts covering Oric Pharmaceuticals, 2 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ORIC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.49, with estimates from -$1.64 to -$1.25 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.69, with estimates from -$1.98 to -$1.37 from 13 analysts.
How many analysts cover ORIC?
15 analysts rate Oric Pharmaceuticals stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ORIC pages: Overview, Earnings, Forecast, Financials, Competitors